In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the January 2022 issue of DTB. They discuss the UK Medicines and Healthcare products Regulatory Agency's decision to license the oral antiviral drug molnupiravir (Lagevrio) and the paucity of publicly available clinical trial data - https://dtb.bmj.com/content/60/1/2. The editors talk about a study that highlighted potentially inappropriate prescribing in middle-aged adults - https://dtb.bmj.com/content/60/1/6. They also review an article on some of the challenges facing people when they try to stop taking antidepressants - https://dtb.bmj.com/content/60/1/7.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

January 2022 - Molnupiravir, potentially harmful prescribing and antidepressant withdrawal reactions

BMJ talk medicine